Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris (PV), Granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA) as a therapeutic, or is recommended (e.g., in Systemic Lupus Erythematosus (SLE) as a cornerstone for disease management.
Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)
Demonstrate the clinical value of Acthar TM in patients with active Psoriatic Arthritis who lack adequate response to DMARDS, and the quantification of response by clinical, serologic and structural parameters.
100 项与 IriSys Research & Development LLC 相关的临床结果
0 项与 IriSys Research & Development LLC 相关的专利(医药)
100 项与 IriSys Research & Development LLC 相关的药物交易
100 项与 IriSys Research & Development LLC 相关的转化医学